Do Atypical Antipsychotics Have Antisuicidal Effects? A Hypothesis-Generating Overview
Open accessThe DOI matches its Crossref record; 95 of the 96 references it cites were found in a registry or an index.
Abstract
Modern antipsychotic drugs are employed increasingly in the treatment of mood disorders as well as psychoses, stimulating interest in their possible contributions to altering suicidal risk. Clozapine remains the only treatment with an FDA-recognized indication for reducing suicidal risk (in schizophrenia). We carried out a systematic, computerized search for reports of studies involving antipsychotic drug treatment and suicidal behaviors. A total of 19 reports provide data with preliminary support for potential suicide risk-reducing effects of olanzapine, quetiapine, ziprasidone, aripiprazole, and asenapine in addition to clozapine, and provide some support for antipsychotic drug treatment in general. These preliminary findings encourage further testing of antipsychotics for effects on suicidal behavior, making use of explicit, pre-planned assessments of suicidal behavior.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second‐generation antipsychotics may be more effective than first‐generation ones in reducing suicide risk, although few studies have examined their impact on suicidality in older patients with schizophrenia 257 .”
From Mental health care for older adults: recent advances and new directions in clinical practice and research (2022) · cites this paper as [257]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393 · cited 7×
“olanzapine in suicidal patients with chronic psychotic disorders [38].”
BackgroundResultInfluentialTiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354 · cited 3×
“2009 [5] 5360 Sz National database Perphenazine Suicide OR: 1.”
BackgroundInfluentialAtypical antipsychotic drugs and the risk of sudden cardiac death
Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806994 · Cited by 1,194 · cited 2×
“Risk of mortality due to natural causes, including sudden death presumably related to cardiac dysfunction, may be increased with older neuroleptics as well as with modern atypical or second-generation antipsychotics (SGAs) [15,16].”
BackgroundTime-related predictors of suicide in major affective disorder
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.9.1189 · Cited by 1,058
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.457 · Cited by 891
Calabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883 · cited 8×
“Reduction in MADRS depression scores was greater with both doses of quetiapine than with duloxetine or placebo, and included improvements in the suicidal item-10 of the ratings, as well as in insomnia.”
BackgroundMethodInfluentialSchizophrenia and suicide: Systematic review of risk factors
Hawton, K., Sutton, L., Haw, C., Sinclair, J., & Deeks, J. J. (2005) · British Journal of Psychiatry · doi:10.1192/bjp.187.1.9 · Cited by 774 · cited 1×
“Risk of suicide appears to be greater among psychotic disorder patients who are younger, male, never married, with evidence of current or previous depression or substance abuse, as well as previous suicide attempts, and who have had relatively good premorbid functioning [8,10,11].”
BackgroundTran, P. V., Hamilton, S. H., Kuntz, A. J., Potvin, J. H., Andersen, S. W., Beasley, C. J., & Tollefson, G. D. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00010 · Cited by 715
(2000) · PubMed · Cited by 685
Cited by
Reynolds, C. F., Jeste, D. V., Sachdev, P. S., & Blazer, D. G. (2022) · World Psychiatry · doi:10.1002/wps.20996 · Cited by 465
Bipolar depression: a major unsolved challenge
Baldessarini, R. J., Vázquez, G. H., & Tondo, L. (2020) · International Journal of Bipolar Disorders · doi:10.1186/s40345-019-0160-1 · Cited by 235
Self-citationOlanzapine versus placebo in adult outpatients with anorexia nervosa: a randomized clinical trial
Attia, E., Steinglass, J. E., Walsh, B. T., Wang, Y., Wu, P., Schreyer, C., Wildes, J., Yilmaz, Z., Guarda, A. S., Kaplan, A. S., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18101125 · Cited by 211
Prevention of suicide by clozapine in mental disorders: systematic review
Masdrakis, V. G., & Baldwin, D. S. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.12.011 · Cited by 103
“…5 meta-analyses (Hennen et al. 2005; Vermeulen et al., 2019 ; Forte et al., 2021 ); Correll et al., 2022 ; Wilkinson et al., 2022 ), and 6 review papers ( Ernst and Goldberg, 2004 ; Aguilar and Siris 2007 ; Kasckow et al., 2011 ; Pompili et al., 2016 ; Zalsman et al., 2016 ; Hawkins et al., 2021 ).”
Taipale, H., Lähteenvuo, M., Tanskanen, A., Mittendorfer-Rutz, E., & Tiihonen, J. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa111 · Cited by 85
Jeon, S., & Kim, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102174 · Cited by 99
Kessler, R. C., Bauer, M. S., Bishop, T. M., Demler, O. V., Dobscha, S. K., Gildea, S. M., Goulet, J. L., Karras, E., Kreyenbuhl, J., Landes, S. J., et al. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00390 · Cited by 52
Forte, A. M., Pompili, M., Imbastaro, B., Luca, G. P. D., Mastrangelo, M., Montalbani, B., & Baldessarini, R. J. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211029738 · Cited by 41
“Moreover, it remains unclear whether other modern medicines indicated for the treatment of schizophrenia or bipolar disorder, usually with prominent initial actions as antagonists or partial agonists at dopamine D2, serotonin 5-HT2A, and other cerebral receptors (Frazer and Blier, 2016), might have antisuicidal benefi…”
BackgroundMethodInfluentialSelf-citationThe Importance of Suicide Risk Formulation in Schizophrenia
Berardelli, I., Rogante, E., Sarubbi, S., Erbuto, D., Lester, D., & Pompili, M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.779684 · Cited by 57
“Furthermore, quetiapine has been shown some potential effects for reducing suicidal risk, not only in patients with schizophrenia (167).”
BackgroundSelf-citationHuang, X., Harris, L. M., Funsch, K. M., Fox, K. R., & Ribeiro, J. D. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02173-9 · Cited by 49
Suicide prevention strategies: An overview of current evidence and best practice elements
Menon, V., Subramanian, K., Selvakumar, N., & Kattimani, S. (2018) · International Journal of Advanced Medical and Health Research · doi:10.4103/ijamr.ijamr_71_18 · Cited by 42
“asenapine; nutraceutical agents such as omega 3 fatty acids; and anesthetic agents such as ketamine.[82,83]”
BackgroundBaldaçara, L., Grüdtner, R. R., Leite, V. D. S., Porto, D. M., Robis, K. P., Fidalgo, T. M., Rocha, G. A., Díaz, A. P., Meleiro, A. M. A. D. S., Corrêa, H., et al. (2021) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2020-1108 · Cited by 48
Chen, X., Ma, L., Bo, Y., Xia, B., Guo, Y., Shang, Y., Yan, F., Huang, E., Shi, W., Ding, R., et al. (2025) · Forensic Science International · doi:10.1016/j.forsciint.2025.112646 · Cited by 30
Aripiprazole relieves motivational anhedonia in rats
Scheggi, S., Pelliccia, T., Gambarana, C., & Montis, M. G. D. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.10.032 · Cited by 25
Clozapine for Treatment-Refractory Aggressive Behavior
Teodorescu, A., Petru, I., Miron, A. A., Petric, P. S., & Dima, L. (2020) · Psychiatric Quarterly · doi:10.1007/s11126-020-09839-x · Cited by 21
Suicide along the Australian coast: Exploring the epidemiology and risk factors
Lawes, J. C., Peden, A. E., Bugeja, L. C., Strasiotto, L., Daw, S., & Franklin, R. C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251938 · Cited by 24
Clozapine in Treatment-Resistant Bipolar Disorder With Suicidality. Three Case Reports
Wilkowska, A., Wiglusz, M. S., & Cubała, W. J. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00520 · Cited by 23
“There are few interesting studies suggesting that newer atypical antipsychotics like quetiapine and asenapine could also reduce suicidal ideation in BD, and they, just like clozapine, should definitely be studied further (29).”
BackgroundNg, V. W. S., Leung, M. T. Y., Chan, E. W., Lee, E. H. M., Hayes, J., Osborn, D., Wing, Y. K., Lau, W. C. Y., Man, K. K. C., & Wong, I. C. K. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115236 · Cited by 18
“Previous studies reported that antipsychotics is associated with an increased risk of suicide, while some studies have shown that atypical antipsychotics may lower the risk (Koek et al., 2012; Pompili et al., 2016).”
Multimodal Machine Learning Prediction of 12‐Month Suicide Attempts in Bipolar Disorder
Pigoni, A., Tesic, I., Pini, C., Enrico, P., Consoli, L. D., Siri, F. M., Nosari, G., Ferro, A., Squarcina, L., Delvecchio, G., et al. (2025) · Bipolar Disorders · doi:10.1111/bdi.70011 · Cited by 22
Rethinking Clozapine: Lights and Shadows of a Revolutionary Drug
Dell’Osso, L., Bonelli, C., Nardi, B., Giovannoni, F., Pronestì, C., Cremone, I. M., Amatori, G., Pini, S., & Carpita, B. (2024) · Brain Sciences · doi:10.3390/brainsci14010103 · Cited by 21
“More generally, Clozapine revealed its superiority to other antipsychotics in preventing suicide in all psychotic disorders, including bipolar disorder with psychotic behaviours [22–24, 83, 86].”
BackgroundSantis, M. D., Lian, J., Huang, X., & Deng, C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111944 · Cited by 16
“Furthermore, recent investigations have also highlighted the potential capability of APD treatment in reducing suicidal risk factors, commonly associated with the aforementioned mental illnesses [14].”
BackgroundDing, R., Zhu, X., Feng, L., Xiao, L., Zhang, L., He, P., & Wang, G. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03115-3 · Cited by 11
Clozapine: A special case of an atypical antipsychotic
Marinho, E. R. (2024) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2024.100140 · Cited by 10
Reinhard, M. A., Seifert, J., Greiner, T., Toto, S., Bleich, S., & Grohmann, R. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01223-x · Cited by 12
Second-Generation Antipsychotics and Suicide: A Commentary
Zuschlag, Z. D. (2021) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.21ac13955 · Cited by 11
O’Leary, J., Purcell, A., Hynes, C., Huet, J., Romanos, M., & McWilliams, S. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000970 · Cited by 9
Asp, M., Ambrus, L., Reis, M., Manninen, S., Fernström, J., Lindqvist, D., & Westrin, Å. (2021) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2021.152264 · Cited by 9
“There is increasing evidence that antipsychotics are an effective augmentation treatment [5 – 8], and although more studies are needed on their potential antisuicidal properties, especially in sub-groups with various psychiatric comorbidities, the approach is promising [9].”
BackgroundYager, J., & Feinstein, R. E. (2017) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000000701 · Cited by 10
“Preliminary studies suggest that suicidal ideation (but not necessarily attempts) may be reduced by several second-generation; antipsychotic; medications including olanzapine, quetiapine, ziprasidone, aripiprazole, and asenapine (Pompili et al., 2016).”
BackgroundPediatric suicide: Review of a preventable tragedy
Greydanus, D. E., Nazeer, A., Qayyum, Z., Patel, D. R., Rausch, R., Hoang, L.-N., Miller, C., Chahin, S. S., Apple, R. W., Saha, G. K., et al. (2024) · Disease-a-Month · doi:10.1016/j.disamonth.2024.101725 · Cited by 13
Clinical Trials Studying Suicide Risk Reduction: Who is Excluded From Participation
Lawrence, R. E., Jaffe, C., Zhao, Y., Wang, Y., & Goldberg, T. E. (2024) · Archives of Suicide Research · doi:10.1080/13811118.2024.2322128 · Cited by 8
“The relationship between antipsychotic medications and suicide risk is similarly undeveloped (Pompili et al., 2016).”
Cabrera‐Mendoza, B., Martínez‐Magaña, J. J., Monroy‐Jaramillo, N., Mendoza, A. D. G., Fresno, C., Fries, G. R., Walss‐Bass, C., López‐Armenta, M., García‐Dolores, F., Díaz‐Otañez, C. E., et al. (2021) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32830 · Cited by 7
“It is estimated that 40% of patients seeking treatment for SUD report at least one suicide attempt in their lifetime (Pompili et al., 2016).”
BackgroundAssociation between attention performance and the different dimensions of DSM-5 depression symptoms
Gjorup, A. L. T., Tolentino, J. C., van Duinkerken, E., Marques, A. C., Filho, Á. D. C., Joaquim, A. M., Neves, V. V., & Schmidt, S. L. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1291670 · Cited by 11
Khan, A., Mar, K. F., Gokul, S., & Brown, W. A. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2018.1514465 · Cited by 6
“illnesses may be decreased by psychotropics (Haukka et al. 2008; Shah et al. 2014; Khan et al. 2013; Pompili et al. 2016; Reutfors et al. 2016).”
BackgroundOchi, S., Inoue, S., Yoshino, Y., Shimizu, H., Iga, J., & Ueno, S. (2019) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2019.17.4.559 · Cited by 6
“vious studies suggested that asenapine may improve depressive symptoms and reduce suicidal risk [21].”
BackgroundImmunopsychiatry: current concepts and future directions
Messina, A. (2026) · Immunologic Research · doi:10.1007/s12026-026-09753-7 · Cited by 6
“Anti-psychotics reduce suicide risk, possibly due to symptom stability and immune-mediated mechanisms that regulate neuroinflammation and stress response [ 15 ].”
Radenković, L., Karanović, J., Pantović-Stefanović, M., Lazić, D., Brajušković, G. N., Ivković, M., Pešović, J., & Pavicevic, D. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094085 · Cited by 252
“However, it is to note that the patients with suicide attempts compared to those without them could also be more prone to more severe forms of disorders and require different treatment, including various medication with known anti-suicidal properties [73–75].”
Ménard, M.-L., Auby, P., Cruzel, C., Cohen, D., Bonnot, O., Askenazy-Gittard, F., Thümmler, S., ETAPE Study Group, Michel, B., Agnès, C., et al. (2022) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/s13034-022-00517-3 · Cited by 5
“Suicidal behavior is highly associated with psychiatric conditions, particularly mood and psychotic disorders [35, 36].”
BackgroundUnmet Needs in Psychiatry: Bipolar Depression
Baldessarini, R. J., Tondo, L., & Vázquez, G. H. (2020) · Springer eBooks · doi:10.1007/978-3-030-42637-8_4 · Cited by 8
Self-citationSuizidalität bei schizophrenen Psychosen: eine aktuelle Übersicht
Knorr, R., & Hoffmann, K. K. P. (2020) · Der Nervenarzt · doi:10.1007/s00115-020-01028-2 · Cited by 6
Mainio, A., Kuusisto, L., Hakko, H. H., & Riipinen, P. K. (2020) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2020.1847323 · Cited by 8
“many mental health disorders, and that the risk is elevated compared to the general population [3,4].”
BackgroundPark, S. A., Son, S., Tae, B. S., Choi, H., Jeong, J.-H., Yoon, H.-K., Shin, C., Kwon, D.-Y., & Ko, Y. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120264 · Cited by 5
Benefit of long-acting paliperidone in Huntington’s disease: a case report
Javelot, H., Meyer, M., Frismand, S., & Hingray, C. (2021) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000346 · Cited by 4
“effects with risperidone are inconsistent, still not assessable for paliperidone (Pompili et al., 2016).”
BackgroundHypomanic symptoms in major depressive disorder: Prognostic impact and treatment issues
Olgiati, P., Kasper, S. F., Zohar, J., Souery, D., Montgomery, S., Ferentinos, P. P., Rujescu, D., Zanardi, R., Fugger, G., Ferri, R., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.10.104 · Cited by 4
Fugger, G., Bartova, L., Dold, M., Fabbri, C., Fanelli, G., Zanardi, R., Kautzky, A., Zohar, J., Souery, D., Mendlewicz, J., et al. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110480 · Cited by 6
Effect of next-step antidepressant treatment on suicidal ideation: findings from the VAST-D trial
Zisook, S., Moutier, C. Y., Rush, A. J., Johnson, G. R., Tal, I., Chen, P., Davis, L. L., Hicks, P. B., WILCOX, J. A., Planeta, B. M., et al. (2023) · Psychological Medicine · doi:10.1017/s0033291723003008 · Cited by 5
“With the possible exception of clozapine for patients with schizophrenia or schizoaffective disorder, the effects of most atypical antipsychotic drugs in reducing suicidal risk have not been adequately tested (Pompili et al., 2016).”
Restorative or Disruptive? Effects of Antidepressants on Sleep Architecture in Depression
Szynkarek, A., Tyrybon, W., Karcz, M., Lustyk, K., Sałaciak, K., & Pytka, K. (2026) · CNS Drugs · doi:10.1007/s40263-026-01297-6 · Cited by 4
“Modern antidepressants have improved the management of depression by targeting a broader range of affective and, to some extent, cognitive symptoms, and some psychoactive agents have shown potential in reducing suicide risk, particularly when used in combination or as augmentation strategies [8, 9].”
Schizophrenia-related suicide mortality in the United States by sex, 1999–2023
Hoopsick, R. A., Khan, T. N., Okon, S. A., Apu, M. A. I., Ni, A., Lee, T., & Yockey, R. A. (2026) · Discover Mental Health · doi:10.1007/s44192-026-00501-9 · Cited by 2
“Conversely, effective antipsychotic treatment may attenuate severe clinical outcomes and psychological distress; clozapine has recognized anti-suicidal effects in schizophrenia, and other atypical antipsychotics have been investigated for possible suicide risk-reducing effects [36].”
Ha, J. H., Lee, E., Lee, D. Y., Cho, Y. H., Lee, H., Park, B., & Son, S. J. (2020) · 신경정신의학 · doi:10.4306/jknpa.2020.59.3.243 · Cited by 2
Aufkommende Suizidgedanken einer bipolaren Patientin nach Einnahme von Pregabalin: ein Fallbericht
Wagner, C., & Montecino, A. (2024) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2374-2182 · Cited by 2
Ameline, A., Blanchot, A., Arbouche, N., Strebler, J., Raul, J., & Kintz, P. (2021) · La Revue de Médecine Légale · doi:10.1016/j.medleg.2021.05.003 · Cited by 2
The clean and dirty ways to reduce suicidality
Sivolap, Y. P., & Portnova, A. A. (2021) · Neurology Bulletin · doi:10.17816/nb71327 · Cited by 1
Insomnische Symptome und Suizidalität – Zusammenhänge und Management
Schwerthöffer, D., & Förstl, H. (2023) · Neuropsychiatrie · doi:10.1007/s40211-023-00466-z · Cited by 2
Suicide and psychiatric disorders
Berardelli, I., Rogante, E., Lamis, D. A., & Pompili, M. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780198843405.003.0018 · Cited by 2
Self-citationSuicide Behaviors among Patients with Substance-Induced Psychosis: A Scoping Review
Palma-Álvarez, R. F., Torales, J. C., Barrios, I., & Salas, D. G. (2025) · Journal of Dual Diagnosis · doi:10.1080/15504263.2025.2559171 · Cited by 3
“In this context, clozapine and, to some extent, other antipsychotics may have antisui-cidal effects in schizophrenia when used over prolonged periods (Pompili et al., 2016; Vermeulen et al., 2019).”
Dysregulated oxidative stress and lactate levels in treatment-resistant schizophrenia
Fang, Y., Zhang, T., Xu, K., Wang, L., He, J., Liao, Y., Yuan, N., & Tang, J. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.106111 · Cited by 3
Meta-analysis of clozapine and somnolence in schizophrenia
Hopkins, M. R., & Miller, B. J. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251364385 · Cited by 4
“…against suicide in patients with schizophrenia compared to other antipsychotics, and it is the only antip-sychotic with the Food and Drug Administration (FDA)-recognized indication for reducing the risk of suicide in patients with schizophrenia (Meltzer et al., 2003; Pompili et al., 2016).”
Jo, E., Kim, G., & Hur, J. (2026) · PLoS ONE · doi:10.1371/journal.pone.0340384 · Cited by 1
“Several attempts have been made to identify factors contributing to NSSI to develop appropriate intervention strategies, which encompass various approaches, including psychological [4] and pharmacological interventions [5] aimed at mitigating associated clinical risks, such as suicidal behavior.”
Vidal, N., Frileux, S., Younès, N., Corruble, E., Brunet-Gouet, É., & Roux, P. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261443684 · Cited by 1
Muneer, A. (2017) · Springer eBooks · doi:10.1007/978-981-10-6577-4_2 · Cited by 2
The Effect of Stressful Life Events and Schizophrenia Polygenic Risk on Suicide in Schizophrenia
Tasmim, S. (2018) · TSpace (University of Toronto)
Psychopharmacology in Rural Settings
Praharaj, S. K., & Andrade, C. (2019) · Studies in computational intelligence · doi:10.1007/978-981-10-0751-4_17-1
Psychopharmacology in Rural Settings
Praharaj, S. K., & Andrade, C. (2020) · Mental health and illness worldwide · doi:10.1007/978-981-10-2345-3_17
Ménard, M.-L., Auby, P., Cruzel, C., Cohen, D., Bonnot, O., Askenazy-Gittard, F., Thümmler, S., & ETAPE Study group (2022) · Research Square · doi:10.21203/rs.3.rs-1894098/v1
Chapter 11. Schizophrenia and Other Psychotic Disorders
Brandt, K., Schrimpf, L., & Lauriello, J. (2020) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375288.lg11
Interventions during the copycat suicide crisis among Thai students: A follow-up study
Jatchavala, C. (2023) · Journal of Medical Society · doi:10.4103/jms.jms_39_22 · Cited by 2
Baldaçara, L., Périco, C. D. A.-M., Pinto, F. I., Grüdtner, R. R., Calfat, E. L. D. B., da Rocha, G. A., Porto, D. M., Leite, V. D. S., Robis, K. P., Fidalgo, T. M., et al. (2024) · Debates em Psiquiatria · doi:10.25118/2763-9037.2024.v14.1262
Matera, E., Petruzzelli, M. G., Margari, L., Masi, G., Pisano, S., Annecchini, F., Carruolo, V., Melibeo, R., Tarantino, F., Garcia‐Argibay, M., et al. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106402
Menard, M.-L., Auby, P., Cruzel, C., Cohen, D., Bonnot, O., Askenazy-Gittard, F., & Thümmler, S. (2022) · Figshare · doi:10.6084/m9.figshare.21547205
Yáñez-Sandoval, O. M., Sampieri-Cabrera, R., & Gutiérrez-Soriano, J. R. (2026) · Discover Psychology · doi:10.1007/s44202-025-00556-9
Qureshi, S., Qutishat, M., Al-Huseini, A., Ikhlaq, R., Ahmed, I., & Al‐Huseini, S. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-025-01779-4
“Notably, atypical antipsychotics have shown potential anti-suicidal effects that are independent of their mood-stabilizing properties (Pompili et al. 2016).”
Linking empowerment and sense of community to life satisfaction through meaning in life
Yasuda, T. (2026) · Discover Psychology · doi:10.1007/s44202-026-00649-z
Beyene, J. A., Zeleke, A. M., Tassew, W. C., Kassie, Z. M., Abebe, A. D., & Ferede, Y. A. (2026) · Discover Psychology · doi:10.1007/s44202-026-00684-w
Miyagawa, R., Takayama, A., Ogawa, Y., & Kawakami, K. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.07.004
Antidépresseurs et risque suicidaire
Nobile, B. (2025) · Elsevier eBooks · doi:10.1016/b978-2-294-78794-2.00043-9
Choi, W.-S., & Min, K. J. (2026) · Springer eBooks · doi:10.1007/978-981-92-1323-8_12
Sepe-Forrest, L., Meraz, R., Chang, Z., Morse, M., Froehlich, T. E., D'Onofrio, B. M., & Quinn, P. D. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122386
Anderson, J., Ronksley, P. E., Kirkham, J. G., Crockford, D. N., & Seitz, D. P. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117406
Marjanovic, Z., & Comeau, T. (2026) · Acta Psychologica · doi:10.1016/j.actpsy.2026.107818
Metadata
- Authors
- Pompili, M., Baldessarini, R., Forte, A., Erbuto, D., Serafini, G., Fiorillo, A., Amore, M., & Girardi, P.
- Affiliations
- McLean Hospital (US)
- Harvard University (US)
- Azienda Ospedaliera Sant'Andrea (IT)
- University of Genoa (IT)
- Department of Psychiatry, University of Naples SUN, Naples I-80138, Italy
- Corresponding author
- Pompili, Maurizio
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2016-10-11
- Volume
- 17
- Issue
- 10
- Pages
- 1700
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5085732
- OpenAlex
- W2530015110
- Cited by
- 78
- References
- 96
- Citations by year
- 2026: 14 · 2025: 9 · 2024: 9 · 2023: 6 · 2022: 5 · 2021: 10 · 2020: 12 · 2019: 4 · 2018: 4 · 2017: 4 · 2016: 1
- FWCI
- 0.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Funders
- Bruce J. Anderson Foundation
- Topics
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- atypical antipsychotics, suicide risk, suicidal behavior, clozapine, olanzapine, quetiapine, ziprasidone, aripiprazole, asenapine, mood disorders, schizophrenia, suicide prevention
- MeSH terms
- Suicide Prevention, Clozapine, Humans, Risk Factors, Schizophrenia, Antipsychotic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.